Symbols / BBLG Stock $1.31 -1.14% Bone Biologics Corporation

Healthcare • Biotechnology • United States • NCM
BBLG (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Jeffrey Frelick
Exch · Country NCM · United States
Market Cap 2.34M
Enterprise Value -2.99M
Income -3.11M
Sales —
FCF (ttm) -1.65M
Book/sh 3.00
Cash/sh 2.97
Employees 2
Insider 10d —
IPO Oct 13, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.81
PEG —
P/S —
P/B 0.44
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 12.77
Current Ratio 13.85
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -2.65
EPS next Y -1.62
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-02
Earnings (prior) 2026-03-02
ROA -41.87%
ROE -70.17%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 1.80M
Shs Float 1.79M
Insider Own 0.04%
Instit Own 2.85%
Short Float 0.40%
Short Ratio 0.62
Short Interest 7.18K
52W High 6.75
vs 52W High -80.67%
52W Low 1.05
vs 52W Low 24.29%
Beta 0.37
Impl. Vol. —
Rel Volume 0.25
Avg Volume 16.91K
Volume 4.23K
Target (mean) $22.20
Tgt Median $22.20
Tgt Low $22.20
Tgt High $22.20
# Analysts 1
Recom None
Prev Close $1.32
Price $1.30
Change -1.14%
About

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$22.20
Mean price target
2. Current target
$1.31
Latest analyst target
3. DCF / Fair value
$-16.55
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.31
Low
$22.20
High
$22.20
Mean
$22.20
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Cost Of Revenue
—
—
—
0.00
Reconciled Cost Of Revenue
—
—
—
0.00
Gross Profit
—
—
—
0.00
Operating Expense
3.23
-23.33%
4.22
-55.25%
9.43
+157.24%
3.67
Research And Development
1.06
-50.23%
2.13
-69.16%
6.91
+337.40%
1.58
Selling General And Administration
2.17
+4.12%
2.09
-17.13%
2.52
+20.84%
2.09
General And Administrative Expense
2.17
+4.12%
2.09
-17.13%
2.52
+20.84%
2.09
Other Gand A
2.17
+4.12%
2.09
-17.13%
2.52
+20.84%
2.09
Total Expenses
3.23
-23.33%
4.22
-55.25%
9.43
+157.24%
3.67
Operating Income
-3.23
+23.33%
-4.22
+55.25%
-9.43
-157.24%
-3.67
Total Operating Income As Reported
-3.23
+23.33%
-4.22
+55.25%
-9.43
-157.24%
-3.67
EBITDA
-3.23
+23.33%
-4.22
+55.25%
-9.43
-157.24%
-3.67
Normalized EBITDA
-3.24
+24.15%
-4.27
+56.89%
-9.91
-50.61%
-6.58
EBIT
-3.23
+23.33%
-4.22
+55.25%
-9.43
-157.24%
-3.67
Total Unusual Items
0.00
-92.23%
0.05
-89.31%
0.48
-83.60%
2.91
Total Unusual Items Excluding Goodwill
0.00
-92.23%
0.05
-89.31%
0.48
-83.60%
2.91
Special Income Charges
—
0.00
+100.00%
-0.41
0.00
Other Special Charges
—
—
0.41
—
Net Income
-3.11
+24.40%
-4.11
+54.04%
-8.95
-502.76%
-1.48
Pretax Income
-3.11
+24.40%
-4.11
+54.04%
-8.95
-502.76%
-1.48
Net Non Operating Interest Income Expense
0.12
+119.16%
0.06
+2879.66%
0.00
+100.26%
-0.73
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
0.12
+119.16%
0.06
+2879.66%
0.00
+100.26%
-0.73
Interest Expense
—
—
—
0.00
Interest Income Non Operating
0.12
+119.16%
0.06
+2879.66%
0.00
0.00
Interest Income
0.12
+119.16%
0.06
+2879.66%
0.00
0.00
Other Income Expense
0.00
-92.23%
0.05
-89.31%
0.48
-83.60%
2.91
Gain On Sale Of Security
0.00
-92.23%
0.05
-94.28%
0.89
-69.35%
2.91
Tax Provision
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-3.11
+24.40%
-4.11
+54.04%
-8.95
-502.76%
-1.48
Net Income From Continuing Operation Net Minority Interest
-3.11
+24.40%
-4.11
+54.04%
-8.95
-502.76%
-1.48
Net Income From Continuing And Discontinued Operation
-3.11
+24.40%
-4.11
+54.04%
-8.95
-502.76%
-1.48
Net Income Continuous Operations
-3.11
+24.40%
-4.11
+54.04%
-8.95
-502.76%
-1.48
Normalized Income
-3.11
+25.23%
-4.16
+55.83%
-9.43
-114.39%
-4.40
Net Income Common Stockholders
-3.11
+57.56%
-7.32
+18.15%
-8.95
-502.76%
-1.48
Otherunder Preferred Stock Dividend
0.00
-100.00%
3.21
0.00
—
Diluted EPS
—
-28.96
+85.81%
-204.06
-9.18%
-186.90
Basic EPS
—
-28.96
+85.81%
-204.06
-9.18%
-186.90
Basic Average Shares
—
0.25
+476.80%
0.04
+452.13%
0.01
Diluted Average Shares
—
0.25
+476.80%
0.04
+452.13%
0.01
Diluted NI Availto Com Stockholders
-3.11
+57.56%
-7.32
+18.15%
-8.95
-502.76%
-1.48
Total Other Finance Cost
—
—
—
0.73
Line Item Trend 2023-12-31
Total Assets
3.74
Current Assets
3.74
Cash Cash Equivalents And Short Term Investments
3.03
Cash And Cash Equivalents
3.03
Cash Financial
3.03
Receivables
0.33
Other Receivables
0.33
Accrued Interest Receivable
—
Prepaid Assets
0.71
Total Non Current Assets
0.00
Total Liabilities Net Minority Interest
0.83
Current Liabilities
0.83
Payables And Accrued Expenses
0.78
Payables
0.36
Accounts Payable
0.36
Current Accrued Expenses
0.41
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Other Current Liabilities
0.06
Total Non Current Liabilities Net Minority Interest
0.00
Stockholders Equity
2.91
Common Stock Equity
2.91
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
0.09
Ordinary Shares Number
0.09
Treasury Shares Number
0.00
Additional Paid In Capital
83.81
Retained Earnings
-80.91
Total Equity Gross Minority Interest
2.91
Total Capitalization
2.91
Working Capital
2.91
Invested Capital
2.91
Net Tangible Assets
2.91
Tangible Book Value
2.91
Current Notes Payable
—
Interest Payable
—
Line Of Credit
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-2.69
+34.76%
-4.12
+56.83%
-9.56
-167.90%
-3.57
Cash Flow From Continuing Operating Activities
-2.69
+34.76%
-4.12
+56.83%
-9.56
-167.90%
-3.57
Net Income From Continuing Operations
-3.11
+24.40%
-4.11
+54.04%
-8.95
-502.76%
-1.48
Other Non Cash Items
—
—
—
0.73
Stock Based Compensation
0.26
+35.77%
0.19
+23.74%
0.15
-42.77%
0.27
Operating Gains Losses
-0.00
+92.23%
-0.05
+94.28%
-0.89
+69.35%
-2.91
Gain Loss On Investment Securities
-0.00
+92.23%
-0.05
+94.28%
-0.89
+69.35%
-2.91
Change In Working Capital
0.17
+210.11%
-0.15
-213.04%
0.13
+178.94%
-0.17
Change In Receivables
-0.01
—
—
—
Change In Prepaid Assets
0.08
-51.81%
0.17
-28.80%
0.25
+125.68%
-0.96
Change In Payables And Accrued Expense
0.09
+127.99%
-0.33
-148.48%
0.67
+13655.69%
0.00
Change In Accrued Expense
0.00
+100.00%
-0.41
-200.00%
0.41
0.00
Change In Payable
0.09
+1.39%
0.09
-64.91%
0.26
+5146.59%
0.00
Change In Account Payable
0.09
+1.39%
0.09
-64.91%
0.26
+5146.59%
0.00
Change In Other Working Capital
—
—
-0.78
-200.00%
0.78
Financing Cash Flow
4.70
+6.26%
4.42
-12.30%
5.04
+13.87%
4.43
Cash Flow From Continuing Financing Activities
4.70
+6.26%
4.42
-12.30%
5.04
+13.87%
4.43
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Short Term Debt Issuance
—
—
—
0.00
Short Term Debt Payments
—
—
—
0.00
Net Short Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
4.70
+79.66%
2.62
-48.13%
5.04
+13.87%
4.43
Proceeds From Stock Option Exercised
0.00
-100.00%
1.81
0.00
—
Changes In Cash
2.01
+572.96%
0.30
+106.62%
-4.51
-622.83%
0.86
Beginning Cash Position
3.33
+9.86%
3.03
-59.85%
7.54
+12.93%
6.68
End Cash Position
5.33
+60.42%
3.33
+9.86%
3.03
-59.85%
7.54
Free Cash Flow
-2.69
+34.76%
-4.12
+56.83%
-9.56
-167.90%
-3.57
Interest Paid Supplemental Data
—
0.00
0.00
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
4.70
+79.66%
2.62
-48.13%
5.04
+13.87%
4.43
Issuance Of Capital Stock
4.70
+79.66%
2.62
-48.13%
5.04
+13.87%
4.43
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category